Roy El Darzi· @Royeldarzi · X·· 13 hours agoScore70
Body · original
Promising results from DeLLphi-305 at #ESMO26!
Tarlatamab + durvalumab maintenance improved median OS from 12.7 to 21.1 months in extensive-stage SCLC.
An exciting step forward in a disease with limited therapeutic options! #LungCancer
26 views · 0 likes · 0 reposts · 0 replies
Conference abstracts
LBA3matched by Presidential Symposium I
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.orgPresented at #ESMO26: In a prespecified interim analysis of a phase 3 trial involving patients with extensive-stage SCLC, the median overall survival was 21.1 months with tarlatamab–durvalumab maintenance therapy and 12.7 months with durvalumab alone. Full DeLLphi-305 trial results: https://nej.md/4iveIgW @myESMO在 X 查看被引用的帖子
Source: Roy El Darzi · x.com